Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Pharmacokinetic evaluation of novel bone-targeting Parathyroid Hormone conjugates to treat Osteoporosis
FY 2018-19
Summary
Currently, there are several classes of compounds used for the treatment and prevention of osteoporosis (OP). Due to patent expirations, lack of potency and selectivity, adverse events and toxicity concerns, companies are searching for novel drug classes to treat OP. To address these concerns, our lab has developed, synthesized and patented a bone-targeting variant of parathyroid hormone (PTH), by conjugation to bisphosphonate (BP) drug bone-seeking functional groups. The bisphosphonate-tethered PTH molecules are thereby able to be guided to the surfaces of bone where they interact with their specific receptors on the surface of bone cells.
The objectives of this project are to refine the separation strategies for our BP-tethered PTH compound and determine the effective therapeutic index, toxicology and efficacy in comparison to unmodified parathyroid hormone using rat as an “in-vivo” animal model, in order to evaluate and prepare this novel bone-targeting compound for clinical trial. Our general hypothesis is that: Bisphosphonate-targeted delivery of parathyroid hormone to bone will increase its concentration to bone cell receptors at the site of its desired antiresorptive or anabolic actions, relative to its presentation to competing receptors in other organs and cells.
The bone-targeting formulation of BP-tethered PTH represents a novel drug compound offers enormous promise in the reduction of serious side-effects experienced with current bone drugs and improved treatments for bone disease. This research will advance our understanding of how the body treats conjugated bone seeking peptide hormones and define new methodology capable of determining pharmacokinetic parameters of drug conjugates.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406518
Name
Wajda Benjamin G
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pharmacokinetic evaluation of novel bone-targeting Parathyroid Hormone conjugates to treat Osteoporosis
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bone Disease; Bone Disorders; Drug Delivery; Hplc; Novel Bone-Seeking Peptide Hormones; Osteoporosis; Parathyroid Hormone; Pharmacokinetics
Abstract
Currently, there are several classes of compounds used for the treatment and prevention of osteoporosis (OP). Due to patent expirations, lack of potency and selectivity, adverse events and toxicity concerns, companies are searching for novel drug classes to treat OP. To address these concerns, our lab has developed, synthesized and patented a bone-targeting variant of parathyroid hormone (PTH), by conjugation to bisphosphonate (BP) drug bone-seeking functional groups. The bisphosphonate-tethered PTH molecules are thereby able to be guided to the surfaces of bone where they interact with their specific receptors on the surface of bone cells.
The objectives of this project are to refine the separation strategies for our BP-tethered PTH compound and determine the effective therapeutic index, toxicology and efficacy in comparison to unmodified parathyroid hormone using rat as an “in-vivo” animal model, in order to evaluate and prepare this novel bone-targeting compound for clinical trial. Our general hypothesis is that: Bisphosphonate-targeted delivery of parathyroid hormone to bone will increase its concentration to bone cell receptors at the site of its desired antiresorptive or anabolic actions, relative to its presentation to competing receptors in other organs and cells.
The bone-targeting formulation of BP-tethered PTH represents a novel drug compound offers enormous promise in the reduction of serious side-effects experienced with current bone drugs and improved treatments for bone disease. This research will advance our understanding of how the body treats conjugated bone seeking peptide hormones and define new methodology capable of determining pharmacokinetic parameters of drug conjugates.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wajda, Benjamin G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~